Ibrutinib does not prevent kidney fibrosis following acute and chronic injury

Ibrutinib does not prevent kidney fibrosis following acute and chronic injury

Abstract Recent studies suggested that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, developed for the treatment of chronic lymphocytic leukemia, may prevent NLRP3 inflammasome activation in macrophages, IL-1β secretion and subsequent development of inflammation and organ fibrosis. The role o...

Full description

Bibliographic Details
Main Authors: Julie Belliere, Audrey Casemayou, Eloïse Colliou, Hélène El Hachem, Clément Kounde, Alexis Piedrafita, Guylène Feuillet, Joost P. Schanstra, Stanislas Faguer
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-91491-x

Internet

https://doi.org/10.1038/s41598-021-91491-x

Similar Items